Health TrialsbyHealthPanel

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

ConditionHypercholesterolaemia
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-130
SponsorAstraZeneca

About this trial

This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naïve patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment of hypercholesterolaemia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participant must be ≥ 18 years of age

Participants with no clinical history of atherosclerotic cardiovascular disease (ASCVD) and a 10-year ASCVD risk estimated as low

Participants who have not received any LLT in the 3 months prior to screening

Disqualifiers

Asian origin.

Statin intolerance

Uncontrolled severe hypertension

Uncontrolled type 2 diabetes mellitus

Trial design

Design model

Factorial

Treatments tested in this trial

  • Laroprovstat

    Drug

    daily oral dose of the Laroprovstat

  • Rosuvastatin 1

    Drug

    daily oral dose of the Rosuvastatin 1

  • Rosuvastatin 2

    Drug

    daily oral dose of the Rosuvastatin 2

  • Laroprovstat/Rosuvastatin 1

    Drug

    daily oral dose of the Laroprovstat/Rosuvastatin 1

  • Placebo to match rosuvastatin

    Drug

    daily oral dose of the Placebo to match Rosuvastatin

  • Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1

    Drug

    daily oral dose of the Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1

  • Laroprovstat/Rosuvastatin 2

    Drug

    daily oral dose of the Laroprovstat/Rosuvastatin 2

  • Placebo to match Laroprovstat/Rosuvastatin 2

    Drug

    daily oral dose of the Placebo to match Laroprovstat/Rosuvastatin 2

Treatment groups

600 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Group A: LaroprovstatActive comparator 3 interventions
Group B: PlaceboPlacebo comparator 3 interventions
Group C: Laroprovstat/Rosuvastatin dose combination 1Experimental treatment 3 interventions
Group D: Laroprovstat/Rosuvastatin dose combination 2Experimental treatment 3 interventions
Group E: Rosuvastatin dose 1Active comparator 3 interventions
Group F: Rosuvastatin dose 2Active comparator 3 interventions

Trial outcomes

Primary outcomes

1

Relative change in LDL-C at 8 weeks

To compare the effect of treatment with FDC laroprovstat/rosuvastatin 2 versus the following on LDL-C at 8 weeks: * Placebo * Rosuvastatin 2 * Laroprovstat

Time frame
8 weeks
2

Relative change in LDL-C at 8 weeks

To compare the effect of treatment with FDC laroprovstat/rosuvastatin 1 versus the following on LDL-C at 8 weeks: * Placebo * Rosuvastatin 1 * Laroprovstat

Time frame
8 weeks

Secondary outcomes

1

Relative change in LDL-C

To compare the effect of treatment with FDC laroprovstat/rosuvastatin 1 versus rosuvastatin 2 alone on LDL-C at 8 weeks

Time frame
8 weeks
2

Relative change in Apo B

To compare the effect of treatment with FDC laroprovstat/rosuvastatin versus the individual components and placebo on apolipoprotein B (Apo B) at 8 weeks

Time frame
8 weeks
3

Relative change in non-HDL-C

To compare the effect of treatment with FDC laroprovstat/rosuvastatin versus the individual components and placebo on non-high-density lipoprotein cholesterol (non-HDL-C) at 8 weeks

Time frame
8 weeks
4

Relative change in total cholesterol

To compare the effect of treatment with FDC laroprovstat/rosuvastatin versus the individual components and placebo on total cholesterol at 8 weeks

Time frame
8 weeks

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

AstraZeneca

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: